Citations 191

Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population

Pharmacology Research & Perspectives | January 24, 2019 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/prp2.461 | PMID 30693088

AbstractThe purpose of this study was to estimate the extent of potential antidepressant overprescribing in a geographically defined U.S. population, and to determine the indications and factors that account for it. We conducted a cohort study of new antidepressant prescriptions for elderly residents of Olmsted County, Minnesota, 2005‐2012, using the Rochester Epidemiology Project medical records‐linkage system. Indications for antidepressants were abstracted from health records for all cohort members. Potential antidepressant overprescribing was defined based on regulatory approval, the level of evidence identified from a standardized drug information database, and multidisciplinary expert review. Predictors of potential antidepressant overprescribing were investigated using logistic regression models, stratified by general antidepressant indication (general medical indication, specific psychiatric diagnosis, and non‐specific psychiatric symptoms). Potential antidepressant overprescribing occurred in 24% of 3199 incident antidepressant prescriptions during the study period, and involved primarily newer antidepressants that were prescribed for non‐specific psychiatric symptoms and subthreshold diagnoses. Potential antidepressant overprescribing was associated with nursing home residence, having a higher number of comorbid medical conditions and outpatient prescribers, taking more concomitant medications, having greater use of urgent or acute care services in the year preceding the index antidepressant prescription, and being prescribed antidepressants via telephone, e‐mail, or patient portal. In conclusion, potential antidepressant overprescribing occurred in elderly persons and involved mainly newer antidepressants used for non‐specific psychiatric symptoms and subthreshold diagnoses, and was associated with indicators of higher clinical complexity or severity and with prescribing without face‐to‐face patient contact.
MULTIMORBIDITY IN POPULATION STUDIES: THE ROCHESTER EPIDEMIOLOGY PROJECT

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 607-607

10.1093/geroni/igy023.2256

Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy

Menopause | October 25, 2018 | Volume: 25 | Issue: 11 | Pages: 1275-1285

10.1097/gme.0000000000001229 | PMID 30358723

Abstract Objective: We studied the long-term risk of depressive and anxiety symptoms in women who underwent bilateral oophorectomy before menopause. Design: We conducted a cohort study among all women residing in Olmsted County, MN, who underwent bilateral oophorectomy before the onset of menopause for a noncancer indication from 1950 through 1987. Each member of the bilateral oophorectomy cohort was matched by age with a referent woman from the same population who had not undergone an oophorectomy. In total, we studied 666 women with bilateral oophorectomy and 673 referent women. Women were followed for a median of 24 years, and depressive and anxiety symptoms were assessed using a structured questionnaire via a direct or proxy telephone interview performed from 2001 through 2006. Results: Women who underwent bilateral oophorectomy before the onset of menopause had an increased risk of depressive symptoms diagnosed by a physician (hazard ratio = 1.54, 95% CI: 1.04-2.26, adjusted for age, education, and type of interview) and of anxiety symptoms (adjusted hazard ratio = 2.29, 95% CI: 1.33-3.95) compared with referent women. The findings remained consistent after excluding depressive or anxiety symptoms that first occurred within 10 years after oophorectomy. The associations were greater with younger age at oophorectomy but did not vary across indications for the oophorectomy. In addition, treatment with estrogen to age 50 years in women who underwent bilateral oophorectomy at younger ages did not modify the risk. Conclusions: Bilateral oophorectomy performed before the onset of menopause is associated with an increased long-term risk of depressive and anxiety symptoms.
F2‐01‐02: PREMENOPAUSAL LOSS OF OVARIAN HORMONES AND DEMENTIA RISK

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_11 | Pages: No page available

10.1016/j.jalz.2018.06.2612

P3‐597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_25 | Pages: No page available

10.1016/j.jalz.2018.06.1963

Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration

JAMA Neurology | October 16, 2018 | Volume: 76 | Issue: 1 | Pages: 95

10.1001/jamaneurol.2018.3057 | PMID 30326011

Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging

Physiology | October 10, 2018 | Volume: 33 | Issue: 6 | Pages: 374-383

10.1152/physiol.00024.2018 | PMID 30303778

Bilateral oophorectomy in premenopausal women is a unique condition causing the abrupt and premature loss of ovarian hormones, primarily estrogen. Bilateral oophorectomy causes an alteration of several fundamental aging processes at the cellular, tissue, organ, and system levels, leading to multimorbidity, frailty, and reduced survival. However, many questions remain unanswered.
In Reply:

Menopause | October 9, 2018 | Volume: 26 | Issue: 1 | Pages: 112-114

10.1097/gme.0000000000001242 | PMID 30300302

Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial

Neurology | April 16, 2018 | Volume: 90 | Issue: 16 | Pages: No page available

10.1212/wnl.0000000000005325 | PMID 29661902

Rochester Epidemiology Project Data Exploration Portal

Preventing Chronic Disease | April 5, 2018 | Volume: 15 | Issue: No issue available | Pages: No page available

10.5888/pcd15.170242 | PMID 29654640